AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
MENLO PARK, Calif., March 27, 2017 -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple, Corium’s President and Chief Executive Officer, will present at the 16th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at 10:00 AM EDT.
A live audio webcast of Corium’s presentation may be accessed here or by visiting “Events & Presentations” in the Investors section of the Company’s website at www.coriumgroup.com. The webcast will be archived on the Corium website for two weeks following the presentation.
About Corium
Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems. Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer's disease. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Mayne Pharma and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. The company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics and additional transdermal products that are being developed with other partners. For further information, please visit www.coriumgroup.com.
Corplex™ and MicroCor® are registered trademarks of Corium International, Inc.
Source: Corium
Investor and Media Contact: SMP Communications Susan M. Pietropaolo [email protected] (201) 923-2049
